This site is intended for US Healthcare Professionals only.

Importance of epeinephrine use

Epinephrine treats type I allergic reactions, including anaphylaxis, but only when it is on hand, and administered quickly and correctly1-3

Rx Icon followed by ~52% OF PATIENTS do not fill or refill their prescription

~52% of patients

do not fill or refill their prescription4*

Icon of a hand serving followed by Almost 2/3 of patients do not consistently carry epinephrine

Almost 2/3 of patients

do not consistently carry epinephrine5-7†

Icon of a stopwatch followed by 83% of patients and caregivers either delay or do not administer epinephrine at all during a type I allergic

83% of patients and caregivers

either delay or do not administer epinephrine at all during a type I allergic reaction8

Earlier treatment with epinephrine increases the likelihood of achieving better patient outcomes, without going to the ER.1,9

*Based on 2023 IQVIA claims data.4

†Based on two surveys (917 adults and parents of children and adolescents who had been prescribed an epinephrine auto-injector and 35 pediatric patients with a documented history of food allergy) and an analysis of 587 food allergic reactions resulting from ingestion.5-7

ER, emergency room.

When seconds matter, a needle-free epinephrine spray is more likely to be carried and used quickly1,10

Hand Icon

76% of patients said they would be more likely to carry a needle-free option10

Rx Icon

Almost half of patients currently not filling their epinephrine needle-injector prescription would be more likely to fill a prescription for a needle-free option11‡

Stopwatch Icon

Patients and caregivers said they’d use a needle-free device earlier, reducing the time to dosing by 45%10§

Needle-free epinephrine may help eliminate the anxiety of using a needle-injector during the onset of an allergic reaction, that could lead to better patient outcomes.1,9,10

‡Based on a survey of 100 patients who had been diagnosed with severe or potentially life-threatening allergies.11

§Based on a 20-minute, double blind, web-based survey which included 100 caregivers and 100 qualifying patients who used an epinephrine injectable device within the 12 months prior to participating in the survey.10

References: 1. Ellis AK, Casale TB, Kaliner M, et al. Development of neffy, an epinephrine nasal spray, for severe allergic reactions. Pharmaceutics. 2024;16(6):811. 2. DalalR, Grujic D. Epinephrine. In: StatPearls [Internet]. https://www.ncbi.nlm.nih.gov/books/NBK482160/. November 23, 2024. Accessed March 18, 2025. 3. Bonds RS, Asawa A, Ghazi AI. Misuse of medical devices: a persistent problem in self-management of asthma and allergic disease. Ann Allergy Asthma Immunol. 2015;114(1):74-76.e2. 4. Data on file. IQVIA Claims Data. ARS Pharmaceuticals Operations, Inc. 2023. 5. WarrenCM, Zaslavsky JM, Kan K, Spergel JM, Gupta RS. Epinephrine auto-injector carriage and use practices among US children, adolescents, and adults. Ann Allergy Asthma Immunol. 2018;121(4):479-489.e2. 6. Curtis C, Stukus D, Scherzer R. Epinephrine preparedness in pediatric patients with food allergy: an ideal time for change. Ann Allergy Asthma Immunol. 2014;112(6):560-562. 7. Brooks C, Coffman A, Erwin E, Mikhail I. Diagnosis and treatment of food allergic reactions in pediatric emergency settings. Ann Allergy Asthma Immunol. 2017;119(5):467-468. 8. Casale TB, Lockey R, Portnoy J, et al. Pharmacokinetics of self-administration of ARS-1 (neffy® nasal spray) 2.0 mg versus manual intramuscular (IM) epinephrine 0.3 mg by health care provider (HCP). Presented at the American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting; February 24, 2023; San Antonio, TX. 9. Brown JC, Simons E, Rudders SA. Epinephrine in the management of anaphylaxis. J Allergy Clin Immunol Pract. 2020;8(4):1186-1195. 10. Kaplan H, Rooney E, Tanimoto S, et al. Epinephrine via needle-free device would be administered faster after symptoms: results of a patient/caregiver survey. Presented at the Annual Scientific Meeting of the American College of Allergy, Asthma and Immunology; November 11, 2022; Louisville, KY. 11. Kaplan H, Rooney E, Tanimoto S, et al. Epinephrine auto-injector (EAI) prescriptions are not filled due to dislike of needles: results of a patient survey. Presented at the American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting; February 24, 2023; San Antonio, TX.

IMPORTANT SAFETY INFORMATION & INDICATION

+

IMPORTANT SAFETY INFORMATION

It is recommended that patients are prescribed and have immediate access to two neffy nasal sprays at all times. In the absence of clinical improvement or if symptoms worsen after initial treatment, administer a second dose of neffy in the same nostril with a new nasal spray starting 5 minutes after the first dose.

INDICATION

neffy is indicated for emergency treatment of type I allergic reactions, including anaphylaxis, in adult and pediatric patients aged 4 years and older who weigh 15 kg or greater.

neffy is for use in the nose only.

Advise patients when to seek emergency medical assistance for close monitoring of the anaphylactic episode and in the event further treatment is required.

Absorption of neffy may be affected by underlying structural or anatomical nasal conditions.

Administer with caution to patients who have heart disease; epinephrine may aggravate angina pectoris or produce ventricular arrhythmias. Arrhythmias, including fatal ventricular fibrillation, have been reported, particularly in patients with underlying cardiac disease or taking cardiac glycosides, diuretics, or anti-arrhythmics.

The presence of a sulfite in neffy should not deter use.

neffy may alter nasal mucosa for up to 2 weeks after administration and increase systemic absorption of nasal products, including neffy.

Patients with certain medical conditions or who take certain medications for allergies, depression, thyroid disorders, diabetes, and hypertension, may be at greater risk for adverse reactions.

Epinephrine can temporarily exacerbate the underlying condition or increase symptoms in patients with the following: hyperthyroidism, Parkinson’s disease, diabetes, renal impairment. Epinephrine should be administered with caution in patients with these conditions, including elderly patients and pregnant women.

Most common adverse reactions are nasal discomfort, headache, rhinorrhea, dizziness, nausea, vomiting, throat irritation, nasal congestion, paresthesia, sneezing, upper respiratory tract congestion, epistaxis, rhinalgia, nasal dryness, dry throat, fatigue, and feeling jittery.

These are not all of the possible side effects of neffy. To report suspected adverse reactions, contact ARS Pharmaceuticals Operations, Inc. at 1-877-MY-NEFFY (877-696-3339) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see full Prescribing Information for neffy.